Jorge Zuniga

Jorge Zuniga has a diverse work experience in the field of scientific research and development. Jorge started their career as a Postdoctoral Fellow at Stanford University in 2007, where they designed and implemented complex X-ray crystallography projects for drug design against botulism. Their work involved co-crystallization of botulinum neurotoxins with peptide inhibitors.

In 2012, Jorge joined a private biotechnology company as a Senior Scientist, where they successfully transferred the first in-house Fab antibody for ELISA assay development. Jorge also sub-cloned anti-LH-hormone Fab antibodies from a phage-display library.

In 2017, they moved to NGM Biopharmaceuticals and took on the role of Scientist II. Their main focus was designing and executing experiments for intracellular delivery of proteinaceous drugs into living cells. Jorge achieved significant success in retargeting a bacterial toxin into breast cancer cells and detecting cell-killing in the pico molar range.

Currently, Jorge is working at Quantum-Si as a Sr Scientist and Staff Scientist. Their work at Quantum-Si involves leading scientific research and developing innovative solutions in the field.

Jorge Zuniga obtained their PhD in Biochemistry from UTHSCSA, where they studied from 2001 to 2007. Jorge also pursued a PhD in Biochemistry with a field of study in Protein NMR at UT Health San Antonio. However, it is not clear when they started or completed this degree.